TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study: NCT03720730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMA
Description: The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2).
Study: NCT01057069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel
Description: Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel
Description: Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel
Description: Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, cyclophosphamide
Description: Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
Description: One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Study: NCT04061681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BIPAMS)
Description: This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
Study: NCT03670914

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WatchPAT 200
Description: The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
Study: NCT03148496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biologic Mesh
Description: Biologic mesh placed during surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small Bites
Description: 0.5 cm x 0.5 cm sutures used
Study: NCT00052884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT04679259

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood
Description: Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive test
Description: Neurocognitive test is performed before surgery and at 7 day after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of delirium
Description: Postoperative delirium is assessed daily during 7 days after surgery.
Study: NCT00240188

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open mesh repair of ventral incisional hernia
Description: For the open procedure, the technique, as described by Chevrel and others was adopted.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic mesh repair of ventral incisional hernia
Description: For the laparoscopic repair, the method of Gagner was adopted
Study: NCT02128282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study: NCT03148496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small Bites
Description: 0.5 cm x 0.5 cm sutures used
Study: NCT02817958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy TIP
Description: Paclitaxel, ifosfamide, and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy TIP
Description: Paclitaxel, ifosfamide, and cisplatin
Study: NCT03829592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: misoprostol in a neutral media
Description: giving misoprostol in a neutral media
Study: NCT00548223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai capsule
Description: Capsule, 0.18g, 2#, Bid\*1year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsule, 0.18g, 2#, Bid\*1year
Study: NCT03829592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol in an acidic media
Description: giving misoprostol in an acidic media

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: misoprostol in an alkaline media
Description: giving misoprostol in an alkaline media
Study: NCT04676906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6861
Description: Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
Study: NCT04818437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE TRAINING
Description: Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
Study: NCT00645385

Intervention type: OTHER
Intervention: MRS Spectroscopy
Description: Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI.
Study: NCT04676906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6860
Description: Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6891
Description: Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
Study: NCT04818437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CORE STABILITY EXERCISES
Description: 1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying
Study: NCT04392557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / alogliptin Oral Product
Description: 850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
Study: NCT03148496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large Bites
Description: 1.0 x 1.0 sutures used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Bites
Description: 1.0 x 1.0 sutures used
Study: NCT02964195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: ALFA WASSERMANN S.p.A.
Study: NCT03534869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
Study: NCT00922649

Intervention type: DEVICE
Group type: OTHER
Intervention: Insulin Pump therapy
Description: Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.

Intervention type: DEVICE
Group type: OTHER
Intervention: Insulin Pump therapy
Description: Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
Study: NCT01044628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentrator
Description: Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham concentrator
Description: Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
Study: NCT01849783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or PO
Study: NCT04392557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / alogliptin Oral Product
Description: 850 or 1000 mg/ 12.5 mg every 12 hours for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / Pioglitazone Pill
Description: (850 mg/15 mg every 12 hours) for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin / Pioglitazone Pill
Description: (850 mg/15 mg every 12 hours) for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple therapy
Description: Metformin / Alogliptin/ Pioglitazone
Study: NCT02128282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study: NCT01705860

Intervention type: BIOLOGICAL
Intervention: Santyl
Study: NCT00536289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blunt needle
Description: Blunt tipped suture needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blunt needle
Description: Blunt tipped suture needle
Study: NCT03512496

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute energy drink - Placebo
Description: Colored water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute energy drink - Caffein
Description: Sugar free energy drink at 5mg/kg caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Acute energy drink - Decaf
Description: Sugar free decaf energy drink (vitamins only)
Study: NCT00946933

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NH4Cl (ammonium chloride)
Description: 0.2 g/kg/day of NH4Cl (ammonium chloride)
Study: NCT01849783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT00958867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program (AT)
Description: Six-month, twice-weekly aerobic training (AT) program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training (RT)
Description: Six-month, twice-weekly resistance training (RT) program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training (S & R; control)
Description: Six-month, twice-weekly stretch \& relax (S \& R; control) program
Study: NCT00946933

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.025 g/kg/day of NaCl (sodium chloride)
Study: NCT01849783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study: NCT00922649

Intervention type: DEVICE
Group type: OTHER
Intervention: Insulin Pump therapy
Description: Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
Study: NCT01235884

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: 1000000000 CFU per day (5 drops) for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops daily for 28 days
Study: NCT01849783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant
Study: NCT00307177

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
Study: NCT02203643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study: NCT00126126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBAR Program
Description: Evidence Based Amputee Rehabilitation Program
Study: NCT00307177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
Study: NCT02664259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
Study: NCT02203643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02128282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
Study: NCT02203643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04276805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation (tVNS)
Description: a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive training
Description: A program of regular mental activities purported to maintain or improve one's cognitive abilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: A program of regular mental activities purported to maintain or improve one's cognitive abilities.
Study: NCT02664259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study: NCT00841919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin and regular insulin
Description: The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lispro insulin
Description: Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
Study: NCT01813812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide 300mg
Study: NCT04561544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowing Who You Are (Becoming): Cultural Identity Intervention
Description: 8-week cultural identity development program led by Alaska Native Elders

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowing Who You Are (Becoming): Cultural Identity Intervention
Description: 8-week cultural identity development program led by Alaska Native Elders
Study: NCT02689180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replacement of furosemide by placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Maintenance of furosemide on usual doses